Thiogenesis Therapeutics, Corp. announced a non brokered private placement for through the issuance of up to 8,000,000 common shares at an issue price of CAD 0.50 per common share to raise up to CAD 4 million on October 24, 2022. The transaction is subject to the approval of the TSX Venture Exchange.

The company anticipates closing of the Offering as soon as practicable subject to receipt of all necessary regulatory approvals. The shares will be subject to a four-month and one day hold period. In connection with the Offering, the company may pay finder's fees to eligible persons in compliance with applicable securities laws and Exchange policies.